Next-Generation Biologics: Improving on Monoclonal Antibodies
Decision Resources
December 12, 2007 35 Pages - SKU: DECR1638050
|
|
Monoclonal antibodies (MAbs) have become the most successful platform for targeted biotherapeutics,
demonstrating high affi nity and specifi city for their target and considerably lower toxicity than small-molecule
drugs. Technological advances in the development and production of MAbs have revealed that antibody
fragments and other smaller, less complex proteins have the potential to overcome many disadvantages
of MAbs, and researchers have begun to explore the therapeutic potential of peptides and nucleic acids as
alternatives to MAbs. The small biotechnology companies that sprang up to commercialize these emerging
technologies have benefi ted from a fl urry of recent licensing and development deals and acquisitions as Big
Pharma begins to see the potential of MAb alternatives and hurries to get in on the action.
Get the Answers You Need to Shape Your Strategy
- The biotechnology and pharmaceutical industries are turning to MAb alternatives as the next generation of targeted biotherapeutics.
- What advantages do small MAb alternatives offer over large MAbs?
- What disadvantages do these novel agents have?
- What choices are possible in the manufacture and formulation of MAb alternatives?
- Because of the high price of biotherapeutic agents, health care payers, government, and patients are exerting pressure on companies to lower the prices of their drugs.
- How could MAb alternatives help companies respond to this pressure and remain profi table?
- How fast and cost-effectively can these agents be brought to market?
- Although some MAb alternatives are already on the market, and despite growing industry confi dence in these novel technologies, the road ahead will not be easy.
- Why is small size not always better?
- What clinical disadvantages may be inherent in MAb alternatives?
- How will the anticipated regulatory guidance on approval of biogenerics in the United States affect the market for MAb alternatives?
Scope
Biotechnology overview:
- Biotherapeutics
- monoclonal antibodies (MAbs)
- emerging MAb alternatives.
Industry overview:
- Biotech and Big Pharma companies
- marketed MAb alternatives
- molecules in development
- by therapeutic area
- industry deals and acquisitions, 2000-2007.
- Production of MAb alternatives
- Biological processes versus cell-free or chemical synthesis
- formulation
- reducing immunogenicity
- cost
- developmental timelines.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Structure of an Antibody
- Improving on Monoclonal Antibodies
- Development
- Manufacturing
- Cost
- Competition and Royalty Stacking
- Delivery
- Immunogenicity
- Industry Interest and Clinical Development
- Remaining Challenges for MAb Alternatives
- Appendix A. Types of Biologic Alternatives to Therapeutic Monoclonal Antibodies
- Tables
- 1. MAb Alternatives in Clinical Development
- 2. Licensing and Comarketing Deals Involving MAb Alternatives, 2000-2007
- 3. Acquisitions Involving MAb Alternatives, 1999-2007
- Figures
- 1. Market Growth of Biotherapeutics and Small-Molecule Drugs, 2002-2006
- 2. Share of Monoclonal Antibodies in the Biologics Market, 2002-2008
- 3. Structure of an Antibody
- 4. MAb Alternatives by Development Stage, 2007
- 5. Deals Involving MAb Alternatives, 2000-2007
- 6. MAb Alternatives in Development, by Therapeutic Area, 2007
Share this report
Other tasks Related Markets Biopharmaceuticals Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
